Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(2 years ago) | |
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(1 year, 9 months ago) | |
US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(1 year, 5 months from now) | |
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(1 year, 11 months from now) |
Zetia is owned by Organon.
Zetia contains Ezetimibe.
Zetia has a total of 10 drug patents out of which 8 drug patents have expired.
Expired drug patents of Zetia are:
Zetia was authorised for market use on 25 October, 2002.
Zetia is available in tablet;oral dosage forms.
Zetia can be used as reduction of elevated plasma sterol and/or stanol levels in a mammal, to reduce plasma cholesterol levels in a mammal, to reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate, to reduce elevated total-c, apo b, and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe in combination with a statin.
The generics of Zetia are possible to be released after 30 April, 2026.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Dec 05, 2011 |
M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: To reduce elevated total-c, apo b, and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe in combination with a statin; To reduce elevated total-c, ldl-c, apo b and non-h...
Dosage: TABLET;ORAL